Search Results

There are 5063 results for: content related to: Melanoma Immunotherapy

  1. You have full text access to this OnlineOpen article
    CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations

    Cancer Medicine

    Volume 4, Issue 5, May 2015, Pages: 661–672, Luis H. Camacho

    Version of Record online : 25 JAN 2015, DOI: 10.1002/cam4.371

  2. You have free access to this content
    Checkpoint blocking antibodies in cancer immunotherapy

    FEBS Letters

    Volume 588, Issue 2, January 21, 2014, Pages: 368–376, Chrisann Kyi and Michael A. Postow

    Version of Record online : 23 OCT 2013, DOI: 10.1016/j.febslet.2013.10.015

  3. Melanoma Treatments: Advances and Mechanisms

    Journal of Cellular Physiology

    Volume 230, Issue 11, November 2015, Pages: 2626–2633, Alexander Marzuka, Laura Huang, Nicholas Theodosakis and Marcus Bosenberg

    Version of Record online : 27 JUL 2015, DOI: 10.1002/jcp.25019

  4. You have free access to this content
    Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab


    Volume 119, Issue 9, 1 May 2013, Pages: 1675–1682, Jeffrey S. Weber, Reinhard Dummer, Veerle de Pril, Celeste Lebbé, F. Stephen Hodi and for the MDX010-20 Investigators

    Version of Record online : 7 FEB 2013, DOI: 10.1002/cncr.27969

  5. You have full text access to this OnlineOpen article
    Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma

    British Journal of Clinical Pharmacology

    Volume 78, Issue 1, July 2014, Pages: 106–117, Yan Feng, Eric Masson, David Dai, Susan M. Parker, David Berman and Amit Roy

    Version of Record online : 20 JUN 2014, DOI: 10.1111/bcp.12323

  6. Systematic Review and Network Meta-Analysis of Overall Survival Comparing 3 mg/kg Ipilimumab With Alternative Therapies in the Management of Pretreated Patients With Unresectable Stage III or IV Melanoma

    The Oncologist

    Volume 17, Issue 11, November 2012, Pages: 1376–1385, Pascale Dequen, Paul Lorigan, Jeroen P. Jansen, Marc van Baardewijk, Mario J.N.M. Ouwens and Srividya Kotapati

    Version of Record online : 28 SEP 2012, DOI: 10.1634/theoncologist.2011-0427

  7. Developing melanoma therapeutics: overview and update

    Wiley Interdisciplinary Reviews: Systems Biology and Medicine

    Volume 5, Issue 3, May/June 2013, Pages: 257–271, John B. Korman and David E. Fisher

    Version of Record online : 13 FEB 2013, DOI: 10.1002/wsbm.1210

  8. Therapeutic cancer vaccines: are we there yet?

    Immunological Reviews

    Volume 239, Issue 1, January 2011, Pages: 27–44, Christopher A. Klebanoff, Nicolas Acquavella, Zhiya Yu and Nicholas P. Restifo

    Version of Record online : 28 DEC 2010, DOI: 10.1111/j.1600-065X.2010.00979.x

  9. You have free access to this content
    Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy

    Pigment Cell & Melanoma Research

    Volume 23, Issue 5, October 2010, Pages: 580–581, Thomas F. Gajewski

    Version of Record online : 1 JUL 2010, DOI: 10.1111/j.1755-148X.2010.00737.x

  10. You have full text access to this OnlineOpen article
    Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

    Annals of the New York Academy of Sciences

    Volume 1291, Issue 1, July 2013, Pages: 1–13, Jedd D. Wolchok, F. Stephen Hodi, Jeffrey S. Weber, James P. Allison, Walter J. Urba, Caroline Robert, Steven J. O'Day, Axel Hoos, Rachel Humphrey, David M. Berman, Nils Lonberg and Alan J. Korman

    Version of Record online : 17 JUN 2013, DOI: 10.1111/nyas.12180

  11. You have free access to this content
    Immunotherapy of cancer in 2012

    CA: A Cancer Journal for Clinicians

    Volume 62, Issue 5, September/October 2012, Pages: 309–335, John M. Kirkwood, Lisa H. Butterfield, Ahmad A. Tarhini, Hassane Zarour, Pawel Kalinski and Soldano Ferrone

    Version of Record online : 10 MAY 2012, DOI: 10.3322/caac.20132

  12. You have free access to this content
    Systematic review: colitis associated with anti-CTLA-4 therapy

    Alimentary Pharmacology & Therapeutics

    Volume 42, Issue 4, August 2015, Pages: 406–417, A. Gupta, K. M. De Felice, E. V. Loftus Jr and S. Khanna

    Version of Record online : 15 JUN 2015, DOI: 10.1111/apt.13281

  13. Ipilimumab and Its Toxicities: A Multidisciplinary Approach

    The Oncologist

    Volume 18, Issue 6, June 2013, Pages: 733–743, Leslie A. Fecher, Sanjiv S. Agarwala, F. Stephen Hodi and Jeffrey S. Weber

    Version of Record online : 17 JUN 2013, DOI: 10.1634/theoncologist.2012-0483

  14. Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

    The Oncologist

    Volume 18, Issue 6, June 2013, Pages: 717–725, Jason J. Luke and F. Stephen Hodi

    Version of Record online : 24 MAY 2013, DOI: 10.1634/theoncologist.2012-0391

  15. You have free access to this content
    New clinical advances in immunotherapy for the treatment of solid tumours


    Volume 145, Issue 2, June 2015, Pages: 182–201, Valentina A. Zavala and Alexis M. Kalergis

    Version of Record online : 30 MAR 2015, DOI: 10.1111/imm.12459

  16. You have free access to this content
    Function but not phenotype of melanoma peptide-specific CD8+ T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696)

    International Journal of Cancer

    Volume 131, Issue 4, 15 August 2012, Pages: 874–884, Carsten Schaefer, Lisa H. Butterfield, Sandra Lee, Grace G. Kim, Carmen Visus, Andreas Albers, John M. Kirkwood and Theresa L. Whiteside

    Version of Record online : 11 JAN 2012, DOI: 10.1002/ijc.26481

  17. You have free access to this content
    Inhibitory receptors as targets for cancer immunotherapy

    European Journal of Immunology

    Volume 45, Issue 7, July 2015, Pages: 1892–1905, Meghan E. Turnis, Lawrence P. Andrews and Dario A. A. Vignali

    Version of Record online : 6 JUL 2015, DOI: 10.1002/eji.201344413

  18. Cancer, Inflammation, and Therapy: Effects on Cytochrome P450–Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents

    Clinical Pharmacology & Therapeutics

    Volume 96, Issue 4, October 2014, Pages: 449–457, R Donald Harvey and E T Morgan

    Version of Record online : 2 JUL 2014, DOI: 10.1038/clpt.2014.143

  19. Cancer Vaccines

    Standard Article


    Peter L Smith and Angus G Dalgleish

    Published Online : 15 NOV 2017, DOI: 10.1002/9780470015902.a0024228

  20. You have free access to this content
    High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma

    British Journal of Dermatology

    Volume 174, Issue 1, January 2016, Pages: 146–151, J. Zaragoza, A. Caille, N. Beneton, G. Bens, F. Christiann, H. Maillard and L. Machet

    Version of Record online : 25 NOV 2015, DOI: 10.1111/bjd.14155